NT 227
Alternative Names: NT-227Latest Information Update: 01 Jul 2021
At a glance
- Originator Medical University of South Carolina
- Developer Medical University of South Carolina; Neuroene Therapeutics
- Class Antiparkinsonians; Small molecules; Vitamins
- Mechanism of Action Vitamin K replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 01 Jul 2021 Neuroene Therapeutics has patent protection for multiple analogues and the corresponding methods for multiple indications (Neuroene Therapeutics website, July 2021)
- 01 Jul 2021 Neuroene Therapeutics has patents pending for multiple analogues and the corresponding methods for multiple indications (Neuroene Therapeutics website, July 2021)
- 01 Jul 2021 Early research in Parkinson's disease in USA (PO) before July 2021 (Neuroene Therapeutics website, July 2021)